import{_ as i,o as a,c as l,f as r}from"./app-0c32d0df.js";const t={};function o(c,e){return a(),l("div",null,e[0]||(e[0]=[r('<h1 id="a-specific-enterotype-derived-from-gut-microbiome-of-older-individuals-enables-favorable-responses-to-immune-checkpoint-blockade-therapy" tabindex="-1"><a class="header-anchor" href="#a-specific-enterotype-derived-from-gut-microbiome-of-older-individuals-enables-favorable-responses-to-immune-checkpoint-blockade-therapy" aria-hidden="true">#</a> A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy</h1><h2 id="results" tabindex="-1"><a class="header-anchor" href="#results" aria-hidden="true">#</a> Results</h2><h3 id="_1-老年癌症患者的icb治疗效果相比年轻患者更好" tabindex="-1"><a class="header-anchor" href="#_1-老年癌症患者的icb治疗效果相比年轻患者更好" aria-hidden="true">#</a> 1. 老年癌症患者的ICB治疗效果相比年轻患者更好</h3><ul><li>ICB可以显著延长患者的生存期，特别是60岁左右的患者</li></ul><h3 id="_2-老年患者的t-cell显示出更高的耗竭和毒性评分" tabindex="-1"><a class="header-anchor" href="#_2-老年患者的t-cell显示出更高的耗竭和毒性评分" aria-hidden="true">#</a> 2. 老年患者的T cell显示出更高的耗竭和毒性评分</h3><ul><li>scRNA-seq</li><li>TMB：肿瘤突变负荷，评估免疫治疗药物的适用性</li><li>年龄、TMB、T cell特征之间存在相关性；在控制TMB的同时进行了偏相关性分析，年龄与T细胞特征存在相关性</li><li>ICB响应者对应更高的T cell毒性评分</li></ul><h3 id="_3-年龄相关t细胞变化可能又肠道菌群调控" tabindex="-1"><a class="header-anchor" href="#_3-年龄相关t细胞变化可能又肠道菌群调控" aria-hidden="true">#</a> 3. 年龄相关T细胞变化可能又肠道菌群调控</h3><ul><li>老年肿瘤小鼠 ICB response 更好</li><li>年老和年轻小鼠肠道微生物存在差异，<em>AKK.muciniphila</em>在年老小鼠中富集，支持进一步探索ICB响应中菌群与年龄的因果关系</li><li>FMT不论受体年龄如何，老年供体的FMT的ICB响应更好（根据供体年龄、受体年龄两两组合分了四组）</li><li>在考虑ICB响应和年龄时，肠道微生物beta多样性不同</li></ul>',8)]))}const d=i(t,[["render",o],["__file","Cell Host Micro-A specific enterotype.html.vue"]]);export{d as default};
